10493-01-3

Basic information

• Product Name: 3,4-Dihydro-5,7-dimethoxy-2-(4-methoxyphenyl)-2H-1-benzopyran-4-ol
• Synonyms: 3,4-Dihydro-5,7-dimethoxy-2-(4-methoxyphenyl)-2H-1-benzopyran-4-ol
• CAS NO: 10493-01-3
• Molecular Formula: C₁₈H₂₀O₅
• Molecular Weight: 0
• Mol File: 10493-01-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4-Dihydro-5,7-dimethoxy-2-(4-methoxyphenyl)-2H-1-benzopyran-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-5,7-dimethoxy-2-(4-methoxyphenyl)-2H-1-benzopyran-4-ol(10493-01-3)
• EPA Substance Registry System: 3,4-Dihydro-5,7-dimethoxy-2-(4-methoxyphenyl)-2H-1-benzopyran-4-ol(10493-01-3)

Safety Data

• Hazardous Substances Data: 10493-01-3(Hazardous Substances Data)

Upstream product

• 66074-95-1 4',5,7-trimethoxyflavanone 
• 487-26-3 Flavanone 

Relevant articles and documents

Cytotoxicity against KB and NCI-H187 cell lines of modified flavonoids from Kaempferia parviflora

Flavones 1-4 isolated from Kaempferia parviflora were used for structural modification. Sixteen flavonoid derivatives, including four new derivatives, were synthesized and evaluated for cytotoxicity against KB and NCI-H187 cell lines. Flavanones 2a-4a demonstrated higher cytotoxic activity than the parent compounds. Cytotoxicity against KB cell line of oxime 1c was about 7 times higher than the ellipticine standard. Interestingly, oximes 1c and 2c exhibited highly potent cytotoxicity against NCI-H187 cell line with IC50 values of 0.014 and 0.23 μM, respectively. Oximes 4c and 5c showed strong cytotoxicity against NCI-H187 cell line with IC50 values of 4.04 and 2.32 μM, respectively.

Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents

Novel compounds are useful as chemotherapeutic, chemopreventative, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) 1wherein R1 through R3 and R5 through R11 are defined herein, and α, β, and γ are optional bonds, providing that when α is absent, β is present, and when β is absent, α is present. When α is present, preferred R4 moieties are selected from O, S, NH and CH2, and when α is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When γ is present, the preferred R5 substituent is O, while when γ is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.